Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Summary of Disaggregation of Revenue

Revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands	Three Months Ended March 31, 2024
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	11	$	—	$	11
Total Drug Products	11		—		11
Concentrate Products
Product Sales – Point-in-time	22,665		20,934		1,731
Total Concentrate Products	22,665		20,934		1,731
Net Revenue	$	22,676	$	20,934	$	1,742

In thousands	Three Months Ended March 31, 2023
Products By Geographic Area	Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	65	$	—	$	65
Total Drug Products	65		—		65
Concentrate Products
Product Sales – Point-in-time	18,131		16,459		1,672
License Fee – Over time	1,472		1,472		—
Total Concentrate Products	19,603		17,931		1,672
Net Revenue	$	19,668	$	17,931	$	1,737

Summary of Contract Balances

The following table provides information about receivables, contract assets, and contract liabilities from contracts with customers.

In thousands	March 31, 2024		December 31, 2023		January 1, 2023
Accounts Receivable, net	$	11,094	$	10,901	$	6,259
Contract Liabilities, which are included in deferred license revenue	$	510	$	521	$	4,331